Valuation: Verastem, Inc.

Market Cap 543M 478M 444M 408M 765M 52.59B 779M 5.31B 2.07B 25.65B 2.04B 1.99B 88.99B P/E 2026 *
-3.9x
P/E 2027 * -5.51x
Enterprise Value 378M 333M 309M 284M 533M 36.61B 542M 3.69B 1.44B 17.86B 1.42B 1.39B 61.95B EV / Sales 2026 *
3.71x
EV / Sales 2027 * 1.87x
Free-Float
99.07%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Verastem, Inc.

1 day-4.13%
1 week+0.75%
Current month+59.03%
1 month+57.79%
3 months+2.79%
6 months-2.64%
Current year-21.31%
1 week 5.7
Extreme 5.7
6.3
1 month 3.43
Extreme 3.43
6.3
Current year 3.43
Extreme 3.43
8.88
1 year 3.43
Extreme 3.43
11.24
3 years 2.1
Extreme 2.1
14.22
5 years 2.1
Extreme 2.1
42.96
10 years 2.1
Extreme 2.1
124.2
Manager TitleAgeSince
Chief Executive Officer 65 01/08/2023
Director of Finance/CFO 39 31/10/2022
Chief Tech/Sci/R&D Officer - 18/04/2024
Director TitleAgeSince
Chairman 62 -
Director/Board Member 65 01/08/2023
Director/Board Member 69 03/05/2017
Date Insider Type Main position Quantity % Market Cap.
22/6/26 Sell

Chief Financial Officer

-4,089 0.0066%
22/6/26 Sell

Chief Executive Officer

-20,871 0.0339%
21/5/26 Free

Director

36,000 0.0410%
Change 5-day change 1-year change 3-year change Capi.($)
-4.13%+0.75%+14.84%-37.11% 543M
+1.23%+0.35%+51.62%+87.98% 55.92B
+1.43%+7.63%+63.85%+69.01% 56.67B
-1.61%+0.22%-19.98%-14.34% 23.28B
-1.01%-0.42%+4.20%+427.22% 23.28B
-0.36%+5.73%+30.99%-3.58% 20.54B
-1.18%+1.52%+26.29%-29.57% 17.78B
-1.44%+5.67%+32.54%+544.11% 15.9B
-2.54%-8.73%+164.11%+289.45% 14.64B
-0.18%+0.17%+25.06%+181.62% 13.99B
Average -0.87%+1.85%+39.35%+151.48% 24.25B
Weighted average by Cap. +0.09%+3.18%+43.37%+137.10%

Financials

2026 *2027 *
Net sales 102M 89.6M 83.23M 76.55M 144M 9.87B 146M 995M 388M 4.81B 382M 374M 16.69B 178M 157M 146M 134M 251M 17.27B 256M 1.74B 680M 8.42B 670M 655M 29.23B
Net income -166M -146M -135M -124M -233M -16.03B -237M -1.62B -631M -7.82B -621M -608M -27.13B -142M -125M -116M -107M -200M -13.76B -204M -1.39B -541M -6.71B -533M -522M -23.28B
Net Debt -165M -145M -135M -124M -233M -15.98B -237M -1.61B -629M -7.79B -619M -606M -27.04B -210M -184M -171M -158M -295M -20.3B -301M -2.05B -799M -9.9B -787M -770M -34.35B
Logo Verastem, Inc.
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
Employees
102
Date Price Change Volume
24/07/26 USD 6.070 -1.78% 32,824
23/07/26 USD 6.180 +4.92% 2,193,680
22/07/26 USD 5.890 -1.83% 1,342,979
21/07/26 USD 6.000 +4.35% 2,532,260
20/07/26 USD 5.750 -4.64% 2,532,687
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
6.180USD
Average target price
15.00USD
Spread / Average Target
+142.72%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VSTM Stock